Benzonitrile as a Proxy for Benzene in the Cold ISM: Low-temperature Rate Coefficients for CN + C₆H₆

The low-temperature reaction between CN and benzene (C₆H₆) is of significant interest in the astrochemical community due to the recent detection of benzonitrile, the first aromatic molecule identified in the interstellar medium (ISM) using radio astronomy. Benzonitrile is suggested to be a low-temperature proxy for benzene, one of the simplest aromatic molecules, which may be a precursor to polycyclic aromatic hydrocarbons. In order to assess the robustness of benzonitrile as a proxy for benzene, low-temperature kinetics measurements are required to confirm whether the reaction remains rapid at the low gas temperatures found in cold dense clouds. Here, we study the C₆H₆ + CN reaction in the temperature range 15–295 K, using the well-established CRESU technique (a French acronym standing for Reaction Kinetics in Uniform Supersonic Flow) combined with pulsed-laser photolysis-laser-induced fluorescence. We obtain rate coefficients, k(T), in the range (3.6–5.4) × 10⁻¹⁰ cm³ s⁻¹ with no obvious temperature dependence between 15 and 295 K, confirming that the CN + C₆H₆ reaction remains rapid at temperatures relevant to the cold ISM

Benzonitrile as a Proxy for Benzene in the Cold ISM: Low-temperature Rate Coefficients for CN + C₆H₆

The low-temperature reaction between CN and benzene (C₆H₆) is of significant interest in the astrochemical community due to the recent detection of benzonitrile, the first aromatic molecule identified in the interstellar medium (ISM) using radio astronomy. Benzonitrile is suggested to be a low-temperature proxy for benzene, one of the simplest aromatic molecules, which may be a precursor to polycyclic aromatic hydrocarbons. In order to assess the robustness of benzonitrile as a proxy for benzene, low-temperature kinetics measurements are required to confirm whether the reaction remains rapid at the low gas temperatures found in cold dense clouds. Here, we study the C₆H₆ + CN reaction in the temperature range 15–295 K, using the well-established CRESU technique (a French acronym standing for Reaction Kinetics in Uniform Supersonic Flow) combined with pulsed-laser photolysis-laser-induced fluorescence. We obtain rate coefficients, k(T), in the range (3.6–5.4) × 10⁻¹⁰ cm³ s⁻¹ with no obvious temperature dependence between 15 and 295 K, confirming that the CN + C₆H₆ reaction remains rapid at temperatures relevant to the cold ISM

Rate Constants of the CN + Toluene Reaction from 15 – 294 K and Interstellar Implications

CN is known for its fast reactions with hydrocarbons at low temperatures, but relatively few studies have focused on the reactions between CN and aromatic molecules. The recent detection of benzonitrile in the interstellar medium, believed to be produced by the reaction of CN and benzene, has ignited interest in studying these reactions. Here, we report rate constants of the CN + toluene (C₇H₈) reaction between 15 and 294 K using a CRESU (Cinétique de Réaction en Ecoulement Supersonique Uniforme; reaction kinetics in uniform supersonic flow) apparatus coupled with the pulsed laser photolysis–laser-induced fluorescence (PLP–LIF) technique. We also present the stationary points on the potential energy surface of this reaction to study the available reaction pathways. We find the rate constant does not change over this temperature range, with an average value of (4.1 ± 0.2) × 10⁻¹⁰ cm³ s⁻¹, which is notably faster than the only previous measurement at 105 K. While the reason for this disagreement is unknown, we discuss the possibility that it is related to enhanced multiphoton effects in the previous work

Rate Constants of the CN + Toluene Reaction from 15 – 294 K and Interstellar Implications

CN is known for its fast reactions with hydrocarbons at low temperatures, but relatively few studies have focused on the reactions between CN and aromatic molecules. The recent detection of benzonitrile in the interstellar medium, believed to be produced by the reaction of CN and benzene, has ignited interest in studying these reactions. Here, we report rate constants of the CN + toluene (C₇H₈) reaction between 15 and 294 K using a CRESU (Cinétique de Réaction en Ecoulement Supersonique Uniforme; reaction kinetics in uniform supersonic flow) apparatus coupled with the pulsed laser photolysis–laser-induced fluorescence (PLP–LIF) technique. We also present the stationary points on the potential energy surface of this reaction to study the available reaction pathways. We find the rate constant does not change over this temperature range, with an average value of (4.1 ± 0.2) × 10⁻¹⁰ cm³ s⁻¹, which is notably faster than the only previous measurement at 105 K. While the reason for this disagreement is unknown, we discuss the possibility that it is related to enhanced multiphoton effects in the previous work

Hybridization of Hyperspectral Imaging Target Detection Algorithm Chains

Detection of a known target in an image can be accomplished using several different approaches. The complexity and number of steps involved in the target detection process makes a comparison of the different possible algorithm chains desirable. Of the different steps involved, some have a more significant impact than others on the final result - the ability to find a target in an image. These more important steps often include atmospheric compensation, noise and dimensionality reduction, background characterization, and detection (matched filtering for this research). A brief overview of the algorithms to be compared for each step will be presented. This research seeks to identify the most effective set of algorithms for a particular image or target type. Several different algorithms for each step will be presented, to include ELM, FLAASH, MNF, PPI, MAXD, the structured background matched filters OSP, and ASD. The chains generated by these algorithms will be compared using the Forest Radiance I HYDICE data set. Finally, receiver operating characteristic (ROC) curves will be calculated for each algorithm chain and, as an end result, a comparison of the various algorithm chains will be presented

Matched Filter Stochastic Background Characterization for Hyperspectral Target Detection

Algorithms exploiting hyperspectral imagery for target detection have continually evolved to provide improved detection results. Adaptive matched filters can be used to locate spectral targets by modeling scene background as either structured (geometric) with a set of endmembers (basis vectors) or as unstructured (stochastic) with a covariance or correlation matrix. These matrices are often calculated using all available pixels in a data set. In unstructured background research, various techniques for improving upon scene-wide methods have been developed, each involving either the removal of target signatures from the background model or the segmentation of image data into spatial or spectral subsets. Each of these methods increase the detection signal-to-background ratio (SBR) and the multivariate normality (MVN) of the data from which background statistics are calculated, thus increasing separation between target and non-target species in the detection statistic and ultimately improving thresholded target detection results. Such techniques for improved background characterization are widely practiced but not well documented or compared. This paper provides a review and comparison of methods in target exclusion, spatial subsetting and spectral pre-clustering, and introduces a new technique which combines these methods. The analysis provides insight into the merit of employing unstructured background characterization techniques, as well as limitations for their practical application

Study of fuel cells using storable rocket propellants Final report, 18 Aug. 1965 - 23 Jun. 1969

Operating fuel cells on gaseous nitrogen tetroxide and aerozine 5

Final analysis of the international observational S-Collate study of peginterferon alfa-2a in patients with chronic hepatitis B

Background and aims Sustained off-treatment immune control is achievable in a proportion of patients with chronic hepatitis B treated with peginterferon alfa-2a. We evaluated on-treatment predictors of hepatitis B surface antigen (HBsAg) clearance 3 years after peginterferon alfa-2a treatment and determined the incidence of hepatocellular carcinoma. Methods A prospective, international, multicenter, observational study in patients with chronic hepatitis B who have been prescribed peginterferon alfa-2a (40KD) in a real-world setting. The primary endpoint was HBsAg clearance after 3 years' follow-up. Results The modified intention-to-treat population comprised 844 hepatitis B e antigen (HBeAg)positive patients (540 [64%] completed 3 years' follow-up), and 872 HBeAg-negative patients (614 [70%] completed 3 years' follow-up). At 3 years' follow-up, HBsAg clearance rates in HBeAg-positive and HBeAg-negative populations, respectively, were 2% (16/844) and 5% (41/872) in the modified intention-to-treat population and 5% [16/328] and 10% [41/ 394] in those with available data. In HBeAg-positive patients with data, Week 12 HBsAg levels <1500, 1500-20,000, and >20,000 IU/mL were associated with HBsAg clearance rates at 3 years' follow-up of 11%, 1%, and 5%, respectively (Week 24 predictability was similar). In HBeAg-negative patients with available data, a 6510% decline vs a <10% decline in HBsAg at Week 12 was associated with HBsAg clearance rates of 16% vs 4%. Hepatocellular carcinoma incidence was lower than REACH-B (Risk Estimation for Hepatocellular Carcinoma in Chronic Hepatitis B) model predictions. Conclusions Sustained off-treatment immune control is achieved with peginterferon alfa-2a in a real-world setting. HBsAg clearance 3 years after completion of peginterferon alfa-2a can be predicted on the basis of on-treatment HBsAg kinetics

“It’s hard to tell”. The challenges of scoring patients on standardised outcome measures by multidisciplinary teams: a case study of Neurorehabilitation

Background Interest is increasing in the application of standardised outcome measures in clinical practice. Measures designed for use in research may not be sufficiently precise to be used in monitoring individual patients. However, little is known about how clinicians and in particular, multidisciplinary teams, score patients using these measures. This paper explores the challenges faced by multidisciplinary teams in allocating scores on standardised outcome measures in clinical practice. Methods Qualitative case study of an inpatient neurorehabilitation team who routinely collected standardised outcome measures on their patients. Data were collected using non participant observation, fieldnotes and tape recordings of 16 multidisciplinary team meetings during which the measures were recited and scored. Eleven clinicians from a range of different professions were also interviewed. Data were analysed used grounded theory techniques. Results We identified a number of instances where scoring the patient was 'problematic'. In 'problematic' scoring, the scores were uncertain and subject to revision and adjustment. They sometimes required negotiation to agree on a shared understanding of concepts to be measured and the guidelines for scoring. Several factors gave rise to this problematic scoring. Team members' knowledge about patients' problems changed over time so that initial scores had to be revised or dismissed, creating an impression of deterioration when none had occurred. Patients had complex problems which could not easily be distinguished from each other and patients themselves varied in their ability to perform tasks over time and across different settings. Team members from different professions worked with patients in different ways and had different perspectives on patients' problems. This was particularly an issue in the scoring of concepts such as anxiety, depression, orientation, social integration and cognitive problems. Conclusion From a psychometric perspective these problems would raise questions about the validity, reliability and responsiveness of the scores. However, from a clinical perspective, such characteristics are an inherent part of clinical judgement and reasoning. It is important to highlight the challenges faced by multidisciplinary teams in scoring patients on standardised outcome measures but it would be unwarranted to conclude that such challenges imply that these measures should not be used in clinical practice for decision making about individual patients. However, our findings do raise some concerns about the use of such measures for performance management

Species Used for Drug Testing Reveal Different Inhibition Susceptibility for 17beta-Hydroxysteroid Dehydrogenase Type 1

Steroid-related cancers can be treated by inhibitors of steroid metabolism. In searching for new inhibitors of human 17beta-hydroxysteroid dehydrogenase type 1 (17β-HSD 1) for the treatment of breast cancer or endometriosis, novel substances based on 15-substituted estrone were validated. We checked the specificity for different 17β-HSD types and species. Compounds were tested for specificity in vitro not only towards recombinant human 17β-HSD types 1, 2, 4, 5 and 7 but also against 17β-HSD 1 of several other species including marmoset, pig, mouse, and rat. The latter are used in the processes of pharmacophore screening. We present the quantification of inhibitor preferences between human and animal models. Profound differences in the susceptibility to inhibition of steroid conversion among all 17β-HSDs analyzed were observed. Especially, the rodent 17β-HSDs 1 were significantly less sensitive to inhibition compared to the human ortholog, while the most similar inhibition pattern to the human 17β-HSD 1 was obtained with the marmoset enzyme. Molecular docking experiments predicted estrone as the most potent inhibitor. The best performing compound in enzymatic assays was also highly ranked by docking scoring for the human enzyme. However, species-specific prediction of inhibitor performance by molecular docking was not possible. We show that experiments with good candidate compounds would out-select them in the rodent model during preclinical optimization steps. Potentially active human-relevant drugs, therefore, would no longer be further developed. Activity and efficacy screens in heterologous species systems must be evaluated with caution